FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilePfizer Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PFE
Pfizer Inc. Stock AnalysisComprehensive stock analysis for Pfizer Inc. (PFE) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPFE
PFE
Pfizer Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PFE
  1. Home
  2. Stocks
  3. Pfizer Inc.

Pfizer Inc.

🇺🇸PFE•NYSE

Pfizer Inc.

🇺🇸PFE•NYSE
Market cap
$164.50B
Sentiment

Your view on PFE

Mkt Cap
$164.50B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Pfizer Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Albert Bourla
Headquarters
235 East 42nd Street, New York City, NY, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Albert Bourla
Headquarters
235 East 42nd Street, New York City, NY, US
Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.

In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.

The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Pfizer Inc. from FRC's valuation model, read against the market price. PFE last traded at $28.86, 40.9× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Pfizer Inc.. Starting points for Pfizer Inc.: P/E 40.9, EPS $0.71, beta 0.30 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Pfizer Inc.. Pfizer Inc. paid $1.72 per share over the last year — a 6.0% yield at the current $28.86 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Pfizer Inc.. Trailing twelve-month EPS for Pfizer Inc. stands at $0.71. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$29.43

average of 14 firms, last 12 months

 

$29.43

Low $25.00

Median $28.50

High $40.00

 

Analyst Ratings

Hold13 firms, last 12 months
  • Strong Buy0
  • Buy5
  • Hold8
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.68$0.70$3.05$2.96
Low estimate$0.61$0.68$2.93$2.75
High estimate$0.82$0.72$3.27$3.18
No. of analysts1141314
Year-ago EPS$0.66$0.75$1.361—
Growth+3.8%-7.0%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$17.22B$14.10B$63.18B$60.71B
Low estimate$16.82B$13.80B$61.68B$59.40B
High estimate$17.55B$14.39B$63.92B$62.70B
No. of analysts941818
Year-ago revenue$17.56B$14.45B$62.58B—
Growth-1.9%-2.4%+1.0%—
Recent analyst actions15 rating and price-target changes, latest Nov 12, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, Investing, Barrons; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Pfizer Inc.. Pfizer Inc. has reported as a listed company since 1972. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PFE15 companies · 8 funds
Compare PFE with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • BMYBristol-Myers Squibb CompanyDrug Manufacturers - General$128.6B
  • GILDGilead Sciences, Inc.Drug Manufacturers - General$207.9B
  • GSKGSK plcDrug Manufacturers - General$101.3B
  • JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
  • LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
  • MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B

More Drug Manufacturers - General companies

  • GLAXFGSK plcOTC$118.6B
  • GRFSGrifols, S.A.NASDAQ$7.4B
  • HAWPFHaw Par Corporation LimitedOTC$3.1B
  • HAWPYHaw Par Corporation LimitedOTC$3.0B
  • JCRRFJCR Pharmaceuticals Co., Ltd.OTC$509M
  • LLY.TOEli Lilly and CompanyTSX$1.8T
  • MIRAMIRA Pharmaceuticals, Inc.NASDAQ$27M

ETFs holding Pfizer Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.27%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.24%
  • IVViShares Core SP 500 ETF$852.9B in assets0.26%
  • SPYState Street SPDR S&P 500 ETF Trust$818.5B in assets0.26%
  • FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets6.82%
  • FDLFirst Trust Morningstar Dividend Leaders Index Fund$8.4B in assets6.18%
  • PPHVanEck Pharmaceutical ETF$1.1B in assets4.69%
  • IHEiShares US Pharmaceuticals ETF$1.7B in assets4.35%

Largest holders first, then the funds most concentrated in PFE.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Pfizer Inc., and how their positions are changing. At a $164.50B market value, institutional positions materially move Pfizer Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Pfizer Inc. executives and directors. Shares of Pfizer Inc. have traded between $20.92 and $27.69 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Pfizer Inc.. Pfizer Inc. is a $164.50B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Pfizer Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Pfizer Inc.. Coverage tracks Pfizer Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Pfizer Inc.

PFE Analysis
Weak
Past2
Growth1
Health3
Profit2
Value1

News

Latest Market News